Neal C. Birnberg, Ph.D.
Dr. Neal C. Birnberg is a Molecular Biologist, with extensive experience in the founding and development of early stage biotechnology companies and the management of complex scientific projects.
Dr. Birnberg received his B.S. in Chemistry in 1976 from Tufts University and his Ph.D. in Biochemistry from the University of Oregon in 1981. Prior to accepting a faculty position at Yale Medical School in the Department of Pharmacology in 1986, Dr. Birnberg was a research fellow in Molecular Biology at the Salk Institute for Biological Studies in La Jolla, California and the Department of Molecular Biology at Massachusetts General Hospital in Boston.
In 1994, Dr. Birnberg took a position as the Scientific Director at Creagen, Inc., which was subsequently acquired by Neurex, Inc. and then subsequently acquired by Elan.
In 1996, Dr. Birnberg and several academic colleagues founded Mercury Therapeutics, Inc., to discover and develop small molecules that target selected protein kinase-mediated signal transduction pathways associated with metabolic disease and cancer. Neal was a great scientist a great person and an ardent Boston sports fan. His perspective, knowledge base and passion are sorely missed.